Want to see BEAM full AI Analyst Report?
Top Page
Beam Therapeutics
(NASDAQ:BEAM)
Select Model
Select Model
Rating:44Neutral
Price Target:
$25.00
▼(-0.40% Downside)
Action:Reiterated
Date:08/04/26
The score is primarily weighed down by weak financial performance (ongoing losses and significant cash burn) and bearish technical signals (price below key moving averages with negative momentum). Valuation provides limited support due to negative earnings and no dividend data, while the recent corporate governance vote is a modest positive but not enough to offset the core profitability and cash-flow risks.
Positive Factors
Proprietary base-editing platform
Beam’s base-editing technology is a durable competitive asset: a platform approach enables multiple therapeutic programs, recurring collaboration/licensing revenue streams, and partner-driven scale. Platform breadth supports long-term optionality across genetic diseases and oncology.
Negative Factors
High cash burn
Persistent negative operating and free cash flow creates ongoing funding needs that can force dilution or debt financing. For a pre-commercial biotech, sustained cash burn means management must prioritize financing or partnerships, which can constrain strategic optionality.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary base-editing platform
Beam’s base-editing technology is a durable competitive asset: a platform approach enables multiple therapeutic programs, recurring collaboration/licensing revenue streams, and partner-driven scale. Platform breadth supports long-term optionality across genetic diseases and oncology.
Read all positive factors
Beam Therapeutics (BEAM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.63B
Dividend YieldN/A
Average Volume (3M)2.52M
Price to Earnings (P/E)―
Beta (1Y)2.39
Revenue Growth157.97%
EPS Growth86.11%
CountryUS
Employees540
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.82
Shares Outstanding102,879,210
10 Day Avg. Volume2,330,625
30 Day Avg. Volume2,517,261
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)2.21
Price to Sales (P/S)19.62
P/FCF Ratio-7.61
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$52.50Price Target Upside109.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-4.39
Revenue Forecast (FY)$56.97M
Beam Therapeutics Business Overview & Revenue Model
Company Description
Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily...
How the Company Makes Money
Beam Therapeutics primarily generates revenue through collaboration and licensing arrangements rather than product sales (its therapeutic candidates have historically been in development). Key revenue streams typically include: (1) upfront payment...
Beam Therapeutics Earnings Call Summary
Earnings Call Date:Feb 24, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Nov 09, 2026
Earnings Call Sentiment Positive
The call presented substantial positive momentum: a new liver-targeted PKU program with strong preclinical efficacy, constructive FDA engagement around an umbrella platform approach, demonstrated LNP and manufacturing capabilities, and a major non-dilutive financing that extends runway into mid-2029. Key risks highlighted include regulatory ambiguity for novel individualized pathways, the large diversity of PAH variants (necessitating personalized approaches), limited public detail on bystander/off-target profiles, and conditional milestone-based financing. On balance, the updates emphasize progress, resources, and clear near-term milestones while acknowledging technical and regulatory uncertainties that are typical for platform-based gene editing development.Positive Updates
New PKU Program (BEAM-304) Initiated and Rapidly Advanced
Beam announced BEAM-304, a liver-targeted base editing program for phenylketonuria (PKU). The company identified two development candidates (including R408W) that together could treat nearly half (~50%) of PKU patients in the U.S. Initial IND-enabling work was advanced in under 2 years with an IND planned to be filed in 2026.
Negative Updates
Regulatory Ambiguity Around 'Plausible Mechanism' Pathway
Draft FDA guidance on the plausible mechanism pathway remains ambiguous about which diseases/variants qualify (ultra-rare vs. more common variants). Beam indicated the framework could help but final applicability to PKU (with both frequent and ultra-rare variants) is uncertain and will require case-by-case discussions with regulators.
Read all updates
Q4-2025 Updates
Positive
Negative
New PKU Program (BEAM-304) Initiated and Rapidly Advanced
Beam announced BEAM-304, a liver-targeted base editing program for phenylketonuria (PKU). The company identified two development candidates (including R408W) that together could treat nearly half (~50%) of PKU patients in the U.S. Initial IND-enabling work was advanced in under 2 years with an IND planned to be filed in 2026.
Read all positive updates
Company Guidance
Beam provided clear program and financial guidance: Beam plans to file the BEAM‑304 IND in 2026 and initiate an open‑label, single‑ascending‑dose Phase I/II in R408W, expects to report updated BEAM‑302 Phase I/II data and a pivotal plan this quarter and to submit the risto‑cel BLA as early as year‑end 2026, and also expects to report initial BEAM‑301 GSDIa data, complete the BEAM‑103 healthy volunteer study and advance in‑vivo HSC editing during 2026. Financially, Beam ended 2025 with $1.25 billion in cash/cash equivalents/marketable securities and announced a Sixth Street facility up to $500 million ( $100M funded at close, up to $300M tied to regulatory/clinical/commercial milestones, plus $100M subject to mutual agreement over a 7‑year term), with a minimum draw of $200M expected to extend runway into mid‑2029 and principal repayment due early 2033. Key program metrics highlighted include two BEAM‑304 candidates that could address nearly half of ~20,000 U.S. PKU patients, preclinical single‑dose (0.3 mg/kg) LNP results that normalized plasma phenylalanine below the 360 µM therapeutic threshold by day 7 in R408W and a second mutation model, and recognition of >1,000 PAH variants worldwide supporting an umbrella/multi‑variant IND approach.Beam Therapeutics Financial Statement Overview
Summary
Income Statement
33
Negative
Balance Sheet
66
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 156.03M | 139.74M | 63.52M | 377.71M | 60.92M | 51.84M |
| Gross Profit | 29.54M | 117.45M | -304.04M | 377.71M | -250.67M | -180.29M |
| EBITDA | -60.29M | -29.92M | -354.78M | -101.63M | -271.53M | -230.06M |
| Net Income | -85.43M | -79.99M | -376.74M | -132.53M | -289.09M | -370.64M |
Balance Sheet | ||||||
| Total Assets | 1.39B | 1.48B | 1.10B | 1.46B | 1.34B | 1.47B |
| Cash, Cash Equivalents and Short-Term Investments | 1.15B | 1.25B | 850.74M | 1.19B | 1.08B | 965.65M |
| Total Debt | 247.36M | 293.88M | 161.43M | 172.69M | 179.00M | 147.64M |
| Total Liabilities | 319.19M | 242.82M | 370.28M | 478.38M | 608.24M | 647.72M |
| Stockholders Equity | 1.07B | 1.24B | 733.54M | 981.33M | 733.47M | 826.74M |
Cash Flow | ||||||
| Free Cash Flow | -372.77M | -360.05M | -356.19M | -182.93M | -26.42M | -113.08M |
| Operating Cash Flow | -359.38M | -345.10M | -347.25M | -149.19M | 22.53M | -66.27M |
| Investing Cash Flow | 189.46M | -121.44M | 185.01M | 71.84M | -461.34M | -294.14M |
| Financing Cash Flow | 107.69M | 478.05M | 7.74M | 276.45M | 111.59M | 756.14M |
Beam Therapeutics Technical Analysis
Neutral
25.10
Price Trends
30.55
Negative
29.29
Negative
28.11
Negative
Market Momentum
-1.18
Negative
46.02
Neutral
68.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BEAM, the sentiment is Neutral. The current price of 25.1 is below the 20-day moving average (MA) of 27.27, below the 50-day MA of 30.55, and below the 200-day MA of 28.11, indicating a neutral trend. The MACD of -1.18 indicates Negative momentum. The RSI at 46.02 is Neutral, neither overbought nor oversold. The STOCH value of 68.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BEAM.
Beam Therapeutics Risk Analysis
Beam Therapeutics disclosed 87 risk factors in its most recent earnings report. Beam Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Beam Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | $3.36B | -1,398.96 | 15.05% | ― | 95.29% | 98.21% | |
61 Neutral | $3.65B | -7.99 | -55.27% | ― | ― | -7.88% | |
60 Neutral | $7.97B | -13.89 | -69.59% | ― | ― | -1.22% | |
52 Neutral | $2.96B | -11.67 | -37.17% | ― | ― | -47.00% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $1.72B | -90.30 | -2.35% | ― | 23.64% | ― | |
44 Neutral | $2.63B | -39.88 | -7.70% | ― | 157.97% | 86.11% |
* Healthcare Sector Average
BEAM
Beam Therapeutics
27.48
10.32
60.09%
DNLI
Denali Therapeutics
24.83
10.91
78.38%
IMVT
Immunovant
39.95
25.19
170.66%
ARQT
Arcutis Biotherapeutics
25.29
11.10
78.22%
IRON
Disc Medicine
77.44
18.85
32.17%
IMCR
Immunocore Holdings
34.00
2.11
6.62%
Beam Therapeutics Corporate Events
Executive/Board ChangesShareholder Meetings
Beam Stockholders Back Board, Leadership at Annual Meeting
Positive
Jun 8, 2026
At its annual meeting of stockholders held on June 3, 2026, Beam Therapeutics Inc. reported that all proposals on the ballot were approved, reflecting broad investor support for the company’s governance and executive leadership. Stockholders...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.